drugset / Trial / NCT06888479

Optimal Timing of Hepatitis B Vaccination After Transplants

NCT06888479

Phase 3 Not yet recruiting 1500 enrolled Institute of Hematology & Blood Diseases Hospital, China
RandomizedFactorialOpen-labelPrevention

Summary

The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.

Timeline

Start
2025-06-01
Primary completion
2028-06-01
Completion
2029-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hepatitis B vaccine Vaccine